Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to $9795.0.

  • Onconetix's Share-based Compensation fell 7853.57% to $9795.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $410458.0, marking a year-over-year increase of 40071.95%. This contributed to the annual value of $438653.0 for FY2024, which is 3302.19% up from last year.
  • As of Q3 2025, Onconetix's Share-based Compensation stood at $9795.0, which was down 7853.57% from $30982.0 recorded in Q2 2025.
  • Onconetix's 5-year Share-based Compensation high stood at $340425.0 for Q4 2024, and its period low was -$234001.0 during Q4 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $45634.0 (2024), whereas its average is $76157.0.
  • In the last 5 years, Onconetix's Share-based Compensation tumbled by 10028.41% in 2024 and then skyrocketed by 409767.74% in 2025.
  • Over the past 3 years, Onconetix's Share-based Compensation (Quarter) stood at -$234001.0 in 2023, then soared by 245.48% to $340425.0 in 2024, then tumbled by 97.12% to $9795.0 in 2025.
  • Its Share-based Compensation was $9795.0 in Q3 2025, compared to $30982.0 in Q2 2025 and $29256.0 in Q1 2025.